Argenx Drug Shows Positive Results in Autoimmune Myositis Phase 3 Trial

Argenx announced positive Phase 3 ALKIVIA study results for VYVGART® Hytrulo (efgartigimod) in autoimmune myositis patients. The drug demonstrated rapid and sustained improvement, meeting primary and key secondary endpoints in immune-mediated necrotizing myopathy and dermatomyositis. This indicates a potentially significant new treatment option for these conditions.